Uro-Vaxom
ApprovedSmall molecule
Uro-Vaxom is one of 47 small molecule programs targeting Neurogenic bladder. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
163 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Maxipime
PfizerPhase 3
Medrol
PfizerPhase 3
Merrem
BB. Braun Medical Inc.
Phase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Piperacillin/tazobactam
PfizerPhase 3
Prulifloxacin
Merck & Co.Phase 3
Amoxicillin/clavulanate Potassium
Johnson & JohnsonPhase 3
Blujepa
GGlaxo Dba Glaxosmithkline
Phase 3
Uro-Vaxom
SSwiss Paraplegic Research, Nottwil
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Uro-Vaxom. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details